Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asunercept - Apogenix

Drug Profile

Asunercept - Apogenix

Alternative Names: APG-101; Apocept; Asinercept; CAN-008

Latest Information Update: 30 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apogenix
  • Developer Apogenix; CANbridge Life Sciences; University Hospital Heidelberg
  • Class Antineoplastics; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors; Fas ligand protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Glioblastoma; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma; Myelodysplastic syndromes

Highest Development Phases

  • Phase II Glioblastoma
  • Preclinical Solid tumours
  • No development reported Graft-versus-host disease; Myelodysplastic syndromes; Myocardial infarction; Stroke

Most Recent Events

  • 19 Nov 2018 CANbridge Life Sciences plans a phase II trial for Glioblastoma multiforme (Recurrent disease, Second line therapy or greater) in China (IV) (NCT03746288)
  • 01 Sep 2018 CANbridge Life Sciences completes a phase I/II trial in Glioblastoma (Newly diagnosed, Combination therapy) in Taiwan (IV) (NCT02853565)
  • 01 Aug 2018 Apogenix receives composition of matter patents for asunercept and its manufacturing process in Europe, Japan, Australia and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top